Study reviews transplant-acquired food allergies, focusing on pediatric patients, particularly liver transplant recipients.

Regeneron Pharmaceuticals, Inc. REGN announced that the blockbuster asthma drug Dupixent (dupilumab) has been recommended by ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

This week's guest Joya Griffin, DVM, DACVD, discusses feline dermatology with host Adam Christman, DVM, MBA ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Fasenra was first approved as an add-on maintenance therapy for patients with uncontrolled severe eosinophilic asthma. It is ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

Paris: Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...